摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-phenylpropyl 4-methylbenzenesulfonate | 23430-41-3

中文名称
——
中文别名
——
英文名称
2-phenylpropyl 4-methylbenzenesulfonate
英文别名
2-Phenylpropyl tosylate
2-phenylpropyl 4-methylbenzenesulfonate化学式
CAS
23430-41-3
化学式
C16H18O3S
mdl
——
分子量
290.383
InChiKey
LWODUZBQQRSKOF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    428.7±24.0 °C(Predicted)
  • 密度:
    1.169±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    20
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    51.8
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    2-phenylpropyl 4-methylbenzenesulfonate 在 sodium iodide 作用下, 以 丙酮 为溶剂, 以50%的产率得到(1-iodopropan-2-yl)benzene
    参考文献:
    名称:
    Conformational interactions between a phenyl ring and a side-chain halide substituent: A 1H NMR and molecular mechanics study of some 2-aryl-1-halopropanes
    摘要:
    DOI:
    10.1016/0584-8539(90)80012-n
  • 作为产物:
    描述:
    2-苯基丙酸吡啶 、 lithium aluminium tetrahydride 作用下, 生成 2-phenylpropyl 4-methylbenzenesulfonate
    参考文献:
    名称:
    Helical Twisting Power of New Chiral Dopants Derived from 2–Phenylpropanoic Acid for Nematic Liquid Crystals
    摘要:
    New chiral dopants for nematic liquid crystals were synthesized using optically active 2-phenylpropanoic acid. The magnitude of helical twisting power (HTP) was largely influenced by the linkages between the asymmetric frame and the core moieties. The results of our experiments clearly showed that a steric effect was important to induce a helical macrostructure.
    DOI:
    10.1080/10587250008023863
点击查看最新优质反应信息

文献信息

  • [EN] BENZOPYRANE AND IMIDAZOLE DERIVATIVES USEFUL FOR THE STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS<br/>[FR] DÉRIVÉS DE STABILISATION DE BENZOPYRANE ET D'IMIDAZOLE UTILISÉS POUR LA STABILISATION DE CHAÎNES LÉGÈRES D'IMMUNOGLOBULINES AMYLOÏDOGÉNIQUES
    申请人:SCRIPPS RESEARCH INST
    公开号:WO2020205683A1
    公开(公告)日:2020-10-08
    In immunoglobulin light chain amyloidosis (AL), the unique antibody light chain (LC) protein that is secreted by monoclonal plasma cells in each patient misfolds and/or aggregates, a process leading to organ degeneration. For treating AL patients, such as those with substantial cardiac involvement who have difficulty tolerating existing chemotherapy regimens, provided herein are small molecule compounds of Formula Ia, Formula Ib, and Formula II that are kinetic stabilizers of the native dimeric structure of full-length LCs, which compounds can slow or stop the amyloidogenicity cascade at its origin.
    在免疫球蛋白轻链淀粉样变性(AL)中,每位患者体内由单克隆浆细胞分泌的独特抗体轻链(LC)蛋白会错误折叠和/或聚集,导致器官退化的过程。为了治疗AL患者,例如那些存在严重心脏受累且难以耐受现有化疗方案的患者,本文提供了化学式Ia、化学式Ib和化学式II的小分子化合物,这些化合物是全长LC的动力学稳定剂,可以减缓或停止淀粉样生成性级联反应的起源。
  • Discovery of Potent Coumarin-Based Kinetic Stabilizers of Amyloidogenic Immunoglobulin Light Chains Using Structure-Based Design
    作者:Nicholas L. Yan、Diogo Santos-Martins、Reji Nair、Alan Chu、Ian A. Wilson、Kristen A. Johnson、Stefano Forli、Gareth J. Morgan、H. Michael Petrassi、Jeffery W. Kelly
    DOI:10.1021/acs.jmedchem.1c00339
    日期:2021.5.13
    interface between the two variable domains of the LC homodimer. We hypothesized that extending the stabilizers beyond this initially characterized binding site would improve affinity. Here, using protease sensitivity assays, we identified stabilizers that can be divided into four substructures. Some stabilizers exhibit nanomolar EC50 values, a 3000-fold enhancement over the screening hits. Crystal structures
    在免疫球蛋白轻链 (LC) 淀粉样变性中,瞬时展开或展开和蛋白水解使 LC 蛋白聚集,从而导致潜在的致命器官损伤。一种在动力学上稳定 LC 的药物可以抑制聚集;然而,LC序列是可变的并且没有天然配体,阻碍了药物开发工作。我们之前确定了高通量筛选命中,这些命中与 LC 同源二聚体的两个可变域之间的界面处的位点结合。我们假设将稳定剂延伸到最初表征的结合位点之外会提高亲和力。在这里,使用蛋白酶敏感性测定,我们确定了可分为四个亚结构的稳定剂。一些稳定剂表现出纳摩尔 EC 50值,比筛选命中提高了 3000 倍。晶体结构揭示了与筛选命中未利用的保守酪氨酸残基的关键 π-π 堆积相互作用。这些数据为开发具有改进的结合选择性和增强的物理化学性质的 LC 稳定剂提供了基础。
  • Amphiphilic Organocatalyst for Schotten-Baumann-Type Tosylation of Alcohols under Organic Solvent Free Condition
    作者:Keisuke Asano、Seijiro Matsubara
    DOI:10.1021/ol900125y
    日期:2009.4.16
    A Tosylation of primary alcohol with tosyl chloride was performed effectively with an N-hexadecylimidazole catalyst in water containing K2CO3. aggregation of the catalyst carrying a hydrophobic methylene chain worked as a substitute for organic solvent.
    N-十六烷基咪唑催化剂可在含K 2 CO 3的水中有效地进行伯醇与甲苯磺酰氯的甲苯磺酸酯化反应。带有疏水性亚甲基链的催化剂的聚集体用作有机溶剂的替代物。
  • Aminomethyl Substituted Bicyclic Aromatic Compounds Suitable for Treating Disorders That Respond to Modulation of the Dopamine D3 Receptor
    申请人:Drescher Karla
    公开号:US20110144146A1
    公开(公告)日:2011-06-16
    The present invention relates to an aminomethyl substituted bicyclic aromatic compound of the formula I wherein Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered C-bound heteroaromatic radical comprising as ring member 1, 2 or 3 heteroatoms which are, independently of each other, selected from O, S and N, and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, 0 and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 -alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a has the meanings given in the claims and in the description; X is a covalent bond or N—R 2 , CHR 2 , CHR 2 CH 2 , N or C—R 2 ; Y is N—R 2a , CHR 2a , CHR 2a CH 2 or CHR 2a CH 2 CH 2 ; is a single bond or a double bond; E is CH 2 or NR 3 ; R 1 is H, C 3 -C 4 -cycloalkyl, C 3 -C 4 -cycloalkylmethyl, C 3 -C 4 -alkenyl, fluorinated C 1 -C 4 -alkyl, fluorinated C 3 -C 4 -cycloalkyl, fluorinated C 3 -C 4 -cycloalkylmethyl, fluorinated C 3 -C 4 -alkenyl, formyl or C 1 -C 3 -alkylcarbonyl; R 1a is H, C 1 C 4 -alkyl, C 3 -C 4 -cycloalkyl, C 3 -C 4 -alkenyl, fluorinated C 1 -C 4 -alkyl, fluorinated C 3 -C 4 -cycloalkyl, fluorinated C 3 -C 4 -alkenyl, R 2 and R 2a each independently are H, CH 3 , CH 2 F, CHF 2 or CF 3 or R 1a and R 2 or R 1a and R 2a together are (CH 2 ) n with n being 1, 2 or 3; R 3 is H or C 1 C 4 -alkyl; R 4 and R 5 independently of each other are H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl or C 1 -C 4 -alkoxy or may form, together with N, a 4-, 5- or 6-membered saturated or unsaturated ring; R 6 and R 7 independently of each other are H or halogen; and the physiologically tolerated acid addition salts thereof.
    本发明涉及一种式子I的氨甲基取代的双环芳香化合物,其中Ar是从苯基、包含1、2或3个杂原子的5-或6元素C-键杂环基团(杂原子独立地选自O、S和N),以及与饱和或不饱和的5-或6元素碳环或杂环环融合的苯环,其中杂环环成员选自N、O和S和/或1、2或3个杂原子含量的基团,每个基团独立地选自NR8,其中R8是H、C1-C4-烷基、氟代C1-C4-烷基、C1-C4-烷基羰基或氟代C1-C4-烷基羰基,环状基团Ar可以携带1、2或3个取代基Ra,其中变量Ra的含义在权利要求和说明书中给出;X是共价键或N-R2、CHR2、CHR2CH2、N或C-R2;Y是N-R2a、CHR2a、CHR2aCH2或CHR2aCH2CH2;是单键或双键;E是CH2或NR3;R1是H、C3-C4-环烷基、C3-C4-环烷基甲基、C3-C4-烯基、氟代C1-C4-烷基、氟代C3-C4-环烷基、氟代C3-C4-环烷基甲基、氟代C3-C4-烯基、甲酰基或C1-C3-烷基羰基;R1a是H、C1-C4-烷基、C3-C4-环烷基、C3-C4-烯基、氟代C1-C4-烷基、氟代C3-C4-环烷基、氟代C3-C4-烯基,R2和R2a各自独立地为H、CH3、CH2F、CHF2或CF3,或者R1a和R2或R1a和R2a一起为(CH2)n,其中n为1、2或3;R3是H或C1-C4-烷基;R4和R5独立地为H、C1-C4-烷基、氟代C1-C4-烷基或C1-C4-烷氧基,或者可以与N一起形成4、5或6元素的饱和或不饱和环;R6和R7独立地为H或卤素;以及其生理耐受的酸加成盐。
  • DUAL-ACTION INHBITORS AND METHODS OF USING SAME
    申请人:deLong Mitchell A.
    公开号:US20120135984A1
    公开(公告)日:2012-05-31
    Provided are compounds, compositions, and methods for treating diseases and conditions wherein an inhibitor of a kinase, such as rho kinase (ROCK), and an inhibitor of one or more of the monoamine transporters, such as NET or SERT, act in concert to improve the condition.
    提供了化合物、组合物和方法,用于治疗疾病和情况,其中激酶抑制剂,如rho激酶(ROCK),和一种或多种单胺转运体抑制剂,如NET或SERT,共同作用以改善病情。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐